Actos ads call for Avandia switch

Share this article:
Takeda ran newspaper ads urging readers to switch to its Actos from rival Avandia after the GlaxoSmithKline drug was hit with FDA marketing restrictions due to safety concerns. The ad, which ran for two weeks in Septmeber and October, bore the headline: “Are you taking Avandia and considering a change?”

The campaign, by AbelsonTaylor and Ketchum, ran in 90 markets and 121 papers, advising patients to “Ask if Actos is right for you” and proffering a 1-800 number and free 30-day trial.

Amid worries about heart risks, FDA decided to keep the drug on the market but with additional restrictions.
An Actos print campaign earlier this year stuck to the science, leveraging Actos' safety profile and stressing that Avandia's safety issues are not a class effect.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.